Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 7;14(7):piaf054.
doi: 10.1093/jpids/piaf054.

Streptococcal Serology Reference Intervals in an Australian Pediatric Cohort

Shu Ki Tsoi  1   2 , Sharon Choo  3 , Lai-Yang Lee  4 , Paul Monagle  5   6   7 , Stephen Hearps  8   9 , Vasiliki Karlaftis  5   6 , Chantal Attard  5   6 , Janet Burgess  10 , Chuong Tran  11 , Sheree Bazeley  12 , Natalie Challen  12 , Andrew C Steer  1   2   5 , Joshua Osowicki  1   2   5 ; HAPPI Kids Study Team
Collaborators, Affiliations

Streptococcal Serology Reference Intervals in an Australian Pediatric Cohort

Shu Ki Tsoi et al. J Pediatric Infect Dis Soc. .

Abstract

Background: Diagnostic criteria for acute rheumatic fever and post-streptococcal glomerulonephritis, the 2 major autoimmune complications of Streptococcus pyogenes infection, include serological evidence of preceding infection. The S. pyogenes proteins, namely streptolysin O and deoxyribonuclease B, are the most widely used targets for clinical streptococcal serology. We aimed to establish age-based reference intervals (RIs) for healthy children in Victoria, Australia, to guide interpretation of anti-streptolysin O (ASO) levels measured by turbidimetry and nephelometry, and anti-deoxyribonuclease B (ADB) levels by nephelometry.

Methods: Serum samples were collected from healthy pediatric cohorts aged 32-week gestation to <18 years at 4 hospitals in Melbourne, Australia, between February 2015 and October 2018. Anti-streptolysin O levels were measured in 2 cohorts: by turbidimetry in cohort 1 and by nephelometry in cohort 2. Anti-deoxyribonuclease B levels were measured by nephelometry in cohort 2. Reference intervals (RIs) for each age group were generated, including 80% upper limit of normal (ULN) cut-offs.

Results: Anti-streptolysin O levels were measured by turbidimetry for 359 samples from cohort 1, and ASO and ADB levels were measured by nephelometry for 360 samples from cohort 2. Anti-streptolysin O levels, measured by turbidimetry, were highest in children 5-9 years of age (80% ULN 346 IU/mL) in cohort 1. For cohort 2, there was a linear age-related increase in ASO levels measured by nephelometry (80% ULN 426 IU/mL in those 15 to <18 years old) and ADB levels were highest in children aged 10-14 years (80% ULN 454 IU/mL).

Conclusions: We established age-specific RI for ASO and ADB levels measured by turbidimetry and nephelometry for healthy Australian children. This study highlights the importance of local method-specific age-based RI to interpret ASO and ADB levels when clinicians suspect acute rheumatic fever or post-streptococcal glomerulonephritis in children.

Keywords: Streptococcus pyogenes; antibodies; child; deoxyribonuclease B; streptolysin O.

Plain language summary

This study established age-specific reference intervals for anti-streptolysin O and anti-DNAse B levels measured by turbidimetry and nephelometry for healthy Australian children. The values are higher than in adults, adding to global data regarding pediatric streptococcal serology values.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Reference Intervals by Age: (A) ASO Level Measured by Turbidimetry (Cohort 1); (B) ASO Level Measured by Nephelometry (Cohort 2); (C) ADB Level Measured by Nephelometry (Cohort 2). Solid Line = 80th Centile; Dotted Lines = 2.5 and 97.5 Centiles; Dashed Line = Median
Figure 2
Figure 2
Bland–Altman Plot of ASO Levels for Cohort 1 Measured by Both Turbidimetry and Nephelometry. Scatter Plot Showing the Mean of ASO Levels Measured by the 2 Methods (X-Axis) and Differences Between ASO Levels Measured by the 2 Methods (Y-Axis). A Mean Difference of −26.4 IU/mL Was Identified (Horizontal Middle Red Dashed Line) With ± 1.96 SD (−100.6 IU/mL, 47.7 IU/mL) Shown in Black Outer Horizontal Dashed Lines
See this image and copyright information in PMC

Similar articles

  • Prescription of Controlled Substances: Benefits and Risks.
    Preuss CV, Kalava A, King KC. Preuss CV, et al. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
  • Different antibiotic treatments for group A streptococcal pharyngitis.
    Hedin K, Thorning S, van Driel ML. Hedin K, et al. Cochrane Database Syst Rev. 2023 Nov 15;11(11):CD004406. doi: 10.1002/14651858.CD004406.pub6. Cochrane Database Syst Rev. 2023. PMID: 37965935 Free PMC article.
  • Effectiveness and safety of vitamin D in relation to bone health.
    Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V. Cranney A, et al. Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088161 Free PMC article.
  • Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Fox T, et al. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
  • The effect of sample site and collection procedure on identification of SARS-CoV-2 infection.
    Davenport C, Arevalo-Rodriguez I, Mateos-Haro M, Berhane S, Dinnes J, Spijker R, Buitrago-Garcia D, Ciapponi A, Takwoingi Y, Deeks JJ, Emperador D, Leeflang MMG, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Davenport C, et al. Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD014780. doi: 10.1002/14651858.CD014780. Cochrane Database Syst Rev. 2024. PMID: 39679851 Free PMC article.
See all similar articles

References

    1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–694. 10.1016/S1473-3099(05)70267-X - DOI - PubMed
    1. Ghamari S, Abbasi-Kangevari M, Saeedi Moghaddam S et al. Rheumatic heart disease is a neglected disease relative to its burden worldwide: findings from global burden of disease 2019. J Am Heart Assoc. 2022;11:e025284. 10.1161/JAHA.122.025284 - DOI - PMC - PubMed
    1. Wannamaker LW, Ayoub EM. Antibody titers in acute rheumatic fever. Circulation. 1960;21:598–614. 10.1161/01.CIR.21.4.598 - DOI - PubMed
    1. Ralph AP, Holt DC, Islam S et al. Potential for molecular testing for group A Streptococcus to improve diagnosis and management in a high-risk population: a prospective study. Open Forum Infect Dis. 2019;6:1-9. 10.1093/ofid/ofz097 - DOI - PMC - PubMed
    1. Taylor A, Morpeth S, Webb R, Taylor S. The utility of rapid group A Streptococcus molecular testing compared with throat culture for the diagnosis of group A streptococcal pharyngitis in a high-incidence rheumatic fever population. J Clin Microbiol. 2021;59:e0097821. 10.1128/JCM.00978-21 - DOI - PMC - PubMed